Tscan Therapeutics Company Insiders
| TCRX Stock | USD 1.67 0.06 3.73% |
Tscan Therapeutics employs about 194 people. The company is managed by 20 executives with a total tenure of roughly 16 years, averaging almost 0.0 years of service per executive, having 9.7 employees per reported executive. Break down of Tscan Therapeutics' management performance can provide insight into the company performance.
| David Southwell Director Independent Director |
Tscan |
Tscan Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.262) % which means that it has lost $0.262 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6508) %, meaning that it created substantial loss on money invested by shareholders. Tscan Therapeutics' management efficiency ratios could be used to measure how well Tscan Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Tscan Therapeutics Workforce Comparison
Tscan Therapeutics is rated third in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,630. Tscan Therapeutics holds roughly 194 in number of employees claiming about 7% of equities under Health Care industry.
Tscan Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tscan Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tscan Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Tscan Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tscan Therapeutics Notable Stakeholders
A Tscan Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Tscan Therapeutics often face trade-offs trying to please all of them. Tscan Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Tscan Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jason CPA | CFO Treasurer | Profile | |
| David Southwell | Independent Director | Profile | |
| Justin McCue | Chief Officer | Profile | |
| Leiden MBA | Principal Treasurer | Profile | |
| Ray Lockard | VP Quality | Profile | |
| Ray MBA | Senior Quality | Profile | |
| Jim Murray | Senior Operations | Profile | |
| Gavin MacBeath | Chief Officer | Profile | |
| Stephen Elledge | CoFounder Board | Profile | |
| Tomasz Kula | CoFounder Board | Profile | |
| Ann Hargraves | Senior Resources | Profile | |
| William MBA | Chief Officer | Profile | |
| Jason Amello | Chief Officer | Profile | |
| Cagan Gurer | Senior Discovery | Profile | |
| Heather Savelle | Vice Relations | Profile | |
| Debora MD | Chief Officer | Profile | |
| Shrikanta MD | Senior Medicine | Profile | |
| Brian JD | CFO VP | Profile | |
| Zoran JD | Chief Secretary | Profile | |
| MPH MD | Chief Officer | Profile |
About Tscan Therapeutics Management Performance
The success or failure of an entity such as Tscan Therapeutics often depends on how effective the management is. Tscan Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Tscan management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Tscan management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Tscan Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 115 people.
Please note, the imprecision that can be found in Tscan Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tscan Therapeutics. Check Tscan Therapeutics' Beneish M Score to see the likelihood of Tscan Therapeutics' management manipulating its earnings.
Tscan Therapeutics Workforce Analysis
Traditionally, organizations such as Tscan Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Tscan Therapeutics within its industry.Tscan Therapeutics Manpower Efficiency
Return on Tscan Therapeutics Manpower
| Revenue Per Employee | 14.5K | |
| Revenue Per Executive | 140.8K | |
| Net Loss Per Employee | 657.2K | |
| Net Loss Per Executive | 6.4M | |
| Working Capital Per Employee | 1.3M | |
| Working Capital Per Executive | 12.8M |
Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.